The case involves multiple applications (M.A. 136/2019, M.A. 675/2019, and M.A. 687/2019) filed by Sterling Biotech Limited through its Resolution Professional under the Corporate Insolvency Resolution Process (CIRP). These applications seek directions against the erstwhile directors (Respondent Nos. 1 to 5) regarding fraudulent and preferential transactions, as well as undervalued transactions. The initial corporate insolvency resolution process was initiated by Andhra Bank, a financial creditor, against Sterling Biotech Limited, which was admitted on June 11, 2018.
Andhra Bank initiated corporate insolvency resolution process (CIRP) against Sterling Biotech Limited, admitted on June 11, 2018. The Resolution Professional (RP) filed applications (M.A. 136/2019, M.A. 675/2019, M.A. 687/2019) alleging fraudulent, preferential, and undervalued transactions by the erstwhile directors. Key facts include: Purchases at exorbitant prices from suppliers with questionable credentials; Payments to Nishant Consultancy without supporting documents; Advances paid to related parties with no direct business nexus; An undervalued land lease to Sterling Healthcare Private Limited, a related entity; A sharp decline in the Corporate Debtor's revenue and profit from 2012 onwards; Significant investments in uncompleted projects, including a gelatin
…Sign in to view the parties.
Andhra Bank's application against Sterling…
The Applicant was…
The case involves multiple applications (M.A. 136/2019, M.A. 675/2019, and M.A. 687/2019) filed by Sterling Biotech Limited through its Resolution Professional under the Corporate Insolvency Resolution Process (CIRP). These applications seek directions against the erstwhile directors (Respondent Nos. 1 to 5) regarding fraudulent and preferential transactions, as well as undervalued transactions. The initial corporate insolvency resolution process was initiated by Andhra Bank, a financial creditor, against Sterling Biotech Limited, which was admitted on June 11, 2018.
Andhra Bank initiated corporate insolvency resolution process (CIRP) against Sterling Biotech Limited, admitted on June 11, 2018. The Resolution Professional (RP) filed applications (M.A. 136/2019, M.A. 675/2019, M.A. 687/2019) alleging fraudulent, preferential, and undervalued transactions by the erstwhile directors. Key facts include: Purchases at exorbitant prices from suppliers with questionable credentials; Payments to Nishant Consultancy without supporting documents; Advances paid to related parties with no direct business nexus; An undervalued land lease to Sterling Healthcare Private Limited, a related entity; A sharp decline in the Corporate Debtor's revenue and profit from 2012 onwards; Significant investments in uncompleted projects, including a gelatin
…Andhra Bank's application against Sterling…
The Applicant was…